Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

HPV16 E6 confers p53-dependent and p53-independent phenotypes in the epidermis of mice deficient for E6AP.

Shai A, Nguyen ML, Wagstaff J, Jiang YH, Lambert PF.

Oncogene. 2007 May 17;26(23):3321-8. Epub 2006 Nov 27.

2.

E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice.

Shai A, Pitot HC, Lambert PF.

Cancer Res. 2010 Jun 15;70(12):5064-73. doi: 10.1158/0008-5472.CAN-09-3307. Epub 2010 Jun 8.

3.

Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.

Martinez-Zapien D, Ruiz FX, Poirson J, Mitschler A, Ramirez J, Forster A, Cousido-Siah A, Masson M, Vande Pol S, Podjarny A, Travé G, Zanier K.

Nature. 2016 Jan 28;529(7587):541-5. doi: 10.1038/nature16481. Epub 2016 Jan 20.

6.

The HPV16 E6 oncoprotein and UVB irradiation inhibit the tumor suppressor TGFβ pathway in the epidermis of the K14E6 transgenic mouse.

Popoca-Cuaya M, Diaz-Chavez J, Hernandez-Monge J, Alvarez-Rios E, Lambert PF, Gariglio P.

Exp Dermatol. 2015 Jun;24(6):430-5. doi: 10.1111/exd.12689. Epub 2015 Apr 16.

PMID:
25776923
7.

Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase.

Kao WH, Beaudenon SL, Talis AL, Huibregtse JM, Howley PM.

J Virol. 2000 Jul;74(14):6408-17.

8.

Involvement of a cellular ubiquitin-protein ligase E6AP in the ubiquitin-mediated degradation of extensive substrates of high-risk human papillomavirus E6.

Matsumoto Y, Nakagawa S, Yano T, Takizawa S, Nagasaka K, Nakagawa K, Minaguchi T, Wada O, Ooishi H, Matsumoto K, Yasugi T, Kanda T, Huibregtse JM, Taketani Y.

J Med Virol. 2006 Apr;78(4):501-7.

PMID:
16482544
9.

Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.

Stutz C, Reinz E, Honegger A, Bulkescher J, Schweizer J, Zanier K, Travé G, Lohrey C, Hoppe-Seyler K, Hoppe-Seyler F.

PLoS One. 2015 Jul 7;10(7):e0132339. doi: 10.1371/journal.pone.0132339. eCollection 2015.

11.

GRIM-19 disrupts E6/E6AP complex to rescue p53 and induce apoptosis in cervical cancers.

Zhou Y, Wei Y, Zhu J, Wang Q, Bao L, Ma Y, Chen Y, Feng D, Zhang A, Sun J, Nallar SC, Shen K, Kalvakolanu DV, Xiao W, Ling B.

PLoS One. 2011;6(7):e22065. doi: 10.1371/journal.pone.0022065. Epub 2011 Jul 12.

12.

E3 ubiquitin ligase E6AP-mediated TSC2 turnover in the presence and absence of HPV16 E6.

Zheng L, Ding H, Lu Z, Li Y, Pan Y, Ning T, Ke Y.

Genes Cells. 2008 Mar;13(3):285-94. doi: 10.1111/j.1365-2443.2008.01162.x.

13.
14.
15.

Requirement of E6AP and the features of human papillomavirus E6 necessary to support degradation of p53.

Cooper B, Schneider S, Bohl J, Jiang Yh, Beaudet A, Vande Pol S.

Virology. 2003 Feb 1;306(1):87-99.

16.
17.

Differential localization of HPV16 E6 splice products with E6-associated protein.

Vaeteewoottacharn K, Chamutpong S, Ponglikitmongkol M, Angeletti PC.

Virol J. 2005 Jun 16;2:50.

18.

HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background.

Massimi P, Shai A, Lambert P, Banks L.

Oncogene. 2008 Mar 13;27(12):1800-4. Epub 2007 Oct 15.

PMID:
17934525
19.

Two distinct activities contribute to human papillomavirus 16 E6's oncogenic potential.

Simonson SJ, Difilippantonio MJ, Lambert PF.

Cancer Res. 2005 Sep 15;65(18):8266-73.

20.

The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6.

Zanier K, Stutz C, Kintscher S, Reinz E, Sehr P, Bulkescher J, Hoppe-Seyler K, Travé G, Hoppe-Seyler F.

PLoS One. 2014 Nov 10;9(11):e112514. doi: 10.1371/journal.pone.0112514. eCollection 2014.

Supplemental Content

Support Center